Seeking Alpha

Savient Pharmaceuticals (SVNT +4.4%) says new data presented at the European League Against...

Savient Pharmaceuticals (SVNT +4.4%) says new data presented at the European League Against Rheumatism congress showed patients with refractory chronic gout also suffering from chronic kidney disease responded to treatment with its drug Krystexxa regardless of its baseline chronic kidney disease stage. The company is seeking approval for Krystexxa in Europe.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector